Difference between revisions of "Procarbazine (Matulane)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
|||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.<ref name="insert">[http://www.matulane.com/pdf/prescribe-info.pdf Procarbazine (Matulane) package insert]</ref><ref>[ | + | Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.<ref name="insert">[http://www.matulane.com/pdf/prescribe-info.pdf Procarbazine (Matulane) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/procarbazine.pdf Procarbazine (Matulane) package insert (locally hosted backup)]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 11: | Line 11: | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
*[[Glioblastoma]] | *[[Glioblastoma]] | ||
| − | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Low-grade glioma]] | *[[Low-grade glioma]] | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
| Line 25: | Line 25: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1969-07-22: Initial FDA approval |
| − | *Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV [[Hodgkin lymphoma|Hodgkin's disease]]. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. ''(Based on Young et al. 1973a, Kolygin 1976, possibly others)'' | + | *Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV [[Classical Hodgkin lymphoma|Hodgkin's disease]]. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. ''(Based on Young et al. 1973a, Kolygin 1976, possibly others)'' |
| − | + | ==History of changes in EMA indication== | |
| + | *1966-10-07: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' NCI-C01810, Ro 4-6467/1 | *'''Code names:''' NCI-C01810, Ro 4-6467/1 | ||
| − | *'''Generic names:''' ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride | + | *'''Generic names:''' ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, procarbazine hydrochloride |
| − | *'''Brand names:''' Indicarb, Matulane, Natulan, Natulanar, P-Carzine | + | *'''Brand names:''' Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine |
==References== | ==References== | ||
| Line 47: | Line 48: | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
[[Category:Glioblastoma medications]] | [[Category:Glioblastoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Low-grade glioma medications]] | [[Category:Low-grade glioma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
| Line 56: | Line 57: | ||
[[Category:FDA approved in 1969]] | [[Category:FDA approved in 1969]] | ||
| + | [[Category:EMA approved in 1966]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 00:09, 6 July 2024
General information
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Diseases for which it is used
- Anaplastic glioma
- CNS lymphoma
- Follicular lymphoma
- Glioblastoma
- Classical Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
Diseases for which it was used
Patient drug information
- Procarbazine (Matulane) patient drug information (Chemocare)[3]
- Procarbazine (Matulane) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1969-07-22: Initial FDA approval
- Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. (Based on Young et al. 1973a, Kolygin 1976, possibly others)
History of changes in EMA indication
- 1966-10-07: EURD
Also known as
- Code names: NCI-C01810, Ro 4-6467/1
- Generic names: ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, procarbazine hydrochloride
- Brand names: Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine
References
Categories:
- Drugs
- Oral medications
- Triazenes
- Alkylating agents
- Human DNA synthesis inhibitors
- Anaplastic glioma medications
- CNS lymphoma medications
- Follicular lymphoma medications
- Glioblastoma medications
- Classical Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Diffuse large B-cell lymphoma medications (historic)
- Non-small cell lung cancer medications (historic)
- Small cell lung cancer medications (historic)
- FDA approved in 1969
- EMA approved in 1966
- WHO Essential Cancer Medicine